Helping Tennessee patients harmed by Dupixent (dupilumab) pursue justice and compensation
If you or a loved one in Tennessee developed lymphoma, T-cell lymphoma (CTCL), or another cancer after using Dupixent (dupilumab), you may be entitled to significant compensation.
At Fob James Law Firm, our Tennessee Dupixent lawsuit lawyers represent individuals harmed by dangerous or defective medications. We fight major pharmaceutical companies like Regeneron and Sanofi for failing to adequately warn patients about the risks of Dupixent.
Why Choose Fob James Law Firm for Your Dupixent Lawsuit
When Dupixent (dupilumab) causes severe reactions, you need a legal team that understands the medical science behind your injuries. At Fob James Law Firm, our attorneys partner with board-certified dermatologists, immunologists, and allergy specialists to review your medical records and document the full extent of your Dupixent-related harm.
Why clients trust our Dupixent legal team:
- Comprehensive medical record evaluations by top specialists
- Deep experience in pharmaceutical and mass tort litigation
- Tennessee lawyers with real federal and state courtroom experience
- Backed by the power and resources of national drug-injury litigation
- Contingency fee representation — pay nothing unless we win
If you were harmed by Dupixent, we have the medical and legal firepower to fight for the compensation you deserve.
Dupixent Lawsuit: Potential Link to Cutaneous T-Cell Lymphoma (CTCL)
Dupixent (dupilumab) is an injectable biologic drug approved by the U.S. Food & Drug Administration (FDA) to treat conditions such as:
- Moderate-to-severe atopic dermatitis (eczema)
- Certain types of asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis (EoE)
Emerging evidence shows a serious concern for some individuals with long-standing, severe eczema. Multiple large database studies and case series report significantly higher rates of cutaneous T-cell lymphoma (CTCL) diagnoses after starting Dupixent, often with rapid clinical worsening or progression shortly after initiation.
While Dupixent does not cause lymphoma in every patient, scientific literature suggests it may unmask or accelerate an underlying lymphoproliferative disorder previously hidden by chronic eczema-like symptoms.
Defendants typically argue that Dupixent only reveals pre-existing lymphoma misdiagnosed as refractory eczema. Yet, with strong dermatopathology, clear biologic mechanisms, time-ordered medical records, and evidence of what the manufacturers knew, plaintiffs can build a compelling case for liability — creating a pathway to substantial verdicts or settlements.
If you were diagnosed with T-cell lymphoma after taking Dupixent, contact our Tennessee Dupixent lawsuit attorneys for a free case evaluation.
The Risk of T-Cell Lymphoma Is Real
Several important database studies and case series suggest that Dupixent users have a higher risk of developing (or worsening) CTCL after use.
Large Database Studies
- JAMA Dermatology (April 2024): Analyzed 19,612 atopic dermatitis (AD) patients via TriNetX database. Dupixent users were 4.1x more likely to develop CTCL (OR 4.1, 95% CI 2.1-8.2) vs. non-users. Risk persisted after adjustments; most diagnoses >1 year post-treatment.
- Dermatologic Therapy (August 2024): TriNetX study of 1.18M AD patients. Dupixent linked to 4.6x higher relative risk (RR 4.6, 95% CI 2.5-8.6). Highest in patients >60 and within first year.
- Journal of Allergy and Clinical Immunology (January 2025): FAERS and RNA-Seq analysis. Dupixent showed 30x higher CTCL reporting rate vs. other meds. Suggested mechanism: IL-13 increase accelerates malignant T-cells.
Case Series & Reviews
- JAAD Case Reports (2022): 7 patients with severe AD developed/worsened CTCL after Dupixent. Symptoms progressed rapidly (average 7.8 months); biopsies showed unmasking of hidden lymphoma.
- International Journal of Dermatology (2023): Systematic review of 18 cases. 100% had >50% body involvement pre-diagnosis; advanced stages (III/IV) common. Recommended biopsies 3-4 months post-start if no improvement.
- Blood Journal (November 2023): 25 MSK Cancer Center patients. Median time to CTCL diagnosis: 10 months. No survival difference vs. non-Dupixent CTCL cases, but progression often accelerated.
Other Insights and Key Findings
- 2025: The FDA is reviewing post-marketing reports of CTCL in Dupixent users but has not issued a recall.
- Current labeling: Dupixent’s warning label does not specifically mention lymphoma, creating a potential “failure-to-warn” claim.
FDA FAERS (as of January 2026): Nearly 300 lymphoma reports (138 CTCL-specific), prompting ongoing review for label updates. No direct causation is proven, but this is a strong signal of correlation.
Who Qualifies for a Dupixent Lawsuit in Tennessee?
You may qualify if you:
- Used Dupixent for eczema, asthma, or sinus issues
- Were later diagnosed with cutaneous T-cell lymphoma (CTCL), Mycosis Fungoides, or Sézary syndrome
- Live in or were prescribed Dupixent in Tennessee
Patients and families may seek compensation for:
- Medical bills and future treatment
- Lost wages or earning capacity
- Pain and suffering
- Emotional distress
- Wrongful death damages (if applicable)
How Long Do I Have to File a Dupixent Lawsuit in Tennessee?
Under Tennessee Code § 28-3-104, most product liability and personal injury claims must be filed within one year from the date of injury or discovery.
That means time is extremely limited to pursue a Dupixent lawsuit. Even if you’re not sure when the drug caused your condition, contact Fob James Law Firm immediately to protect your rights.
Dupixent Litigation Updates (as of November 2025)
| Date | Event |
|---|---|
| June 2018 | Early studies suggest Dupixent may affect T-cell activity linked to lymphoma. |
| April 2024 | Cohort study finds increased risk of CTCL among Dupixent users. |
| November 2024 | Regeneron sues Sanofi over Dupixent commercial rights, signaling scrutiny. |
| Mid-2025 | FDA continues to monitor reports; no recall or black-box warning yet. |
| November 2025 | Law firms across the U.S., including Tennessee, begin filing individual lawsuits. |
Frequently Asked Questions
Is there a Dupixent recall?
Not yet. As of 2025, the FDA has not recalled Dupixent, but the agency continues to review reports of lymphoma and other serious side effects.
What cancers are linked to Dupixent?
The primary cancer type linked to Dupixent is cutaneous T-cell lymphoma (CTCL). Other reported cases include Mycosis Fungoides and Sézary syndrome.
Can I join a class action or MDL?
Currently, Dupixent lawsuits are being filed individually. If a federal MDL is established, your Tennessee lawyer can help transfer your case to that proceeding.
What does it cost to hire a Dupixent lawyer?
Fob James Law Firm works on a contingency fee basis — you pay nothing unless we win your case.
How do I start a Dupixent claim in Tennessee?
Call our Birmingham office or fill out our online form. Our team will review your case, explain your rights, and guide you through the next steps.
Contact a Tennessee Dupixent Lawsuit Lawyer
If you or a family member developed cancer after taking Dupixent, don’t wait. Call Fob James Law Firm today for a free, confidential consultation.
📞 (866) 837-1010 or submit your information online.
Let our Dupixent lawsuit lawyers in Tennessee help you fight for the justice and compensation you deserve.